[A25-136] Avapritinib (indolent systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V
Last updated 02.02.2026
Project no.:
A25-136
Commission:
Commission awarded on 31.10.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-136
| Project no. | Title | Status |
|---|---|---|
| A25-138 | Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-137 | Avapritinib (advanced systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G23-32 | Avapritinib (indolent systemic mastocytosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| G22-10 | Avapritinib (advanced systemic mastocytosis) – Assessment according to §35a (para. 1., sentence 11) | Commission completed |
| G20-26 | Avapritinib (GIST) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |